E rosette formation by peripheral blood T lymphocytes was studied during photochemotherapy (PUV A) of psoriasis. Prior to PUV A treatment the percentage of E rosette forming cells was found to be markedly decreased in patients with active psoriasis, whereas it was normal ill those with inactive skin lesions.
hr, was related to combined 8 MOP + UV A action, but not to 8 MOP or UV A irradiation alone. T lymphocytes reacquired an initial number of E rosette forming cells 48 hr after the last PUV A exposure.
PUV A-induced inhibition of E rosette formation was most prominent in patients with inactive psoriasis in whom the initial percentage of E rosettes before treatment was normal. A lesser degree of decrease of E rosette forming cells after PUV A exposure was observed in patients with active psoriasis and reduced initial percentage of E rosettes_ The suppression of E rosette formation caused by PUV A exposure was related to the presence of psoriatic lesions, since it could not be demonstrated after clearing of skin changes.
Irrespective of preceding activity of the disease, E rosette formation showed a gradual improvement with PUV A therapy. The reduction in the percentage of E rosettes completely disappeared in the fourth week of PUV A treatment, which was correlated with healing of skin lesions. Almost all patients with psoriasis (85%) recovered normal E rosette function up to 1 mo after termination of PUV A treatment.
Patients with psoriasis have been found to have abnormalities in cell-mediated immune response. The frequency and intensity of experimentally induced hypersensitivity to DNCB was significantly lower in the patients than in normal population [1, 2] . Decrease in lymphocyte response to nonspecific mitogens (PHA [phytohemagglutinin], Con A [concanavalin A], and PWM [pokeweed mitogen]) was also reported by several a uthors [3] [4] [5] .
Manuscript received May 15, 1978; accepted for publication November 13, 1978 .
Reprint requests to: Wieslaw Glinski, M.D., Department of Dermatology, Academy of Medicine, 82 A Koszykowa Str., 02008 Warsaw, Poland.
Abbreviations: Con A: concanavalin A PHA: phytohemagglutinin PUV A: photochemotherapy PWM: pokeweed mitogen These abnormalities were not related to the reduction of T cell count. Decreased E rosette formation in patients with psoriasis, previously described by Cormane et al [6] Guilhou et al [4] , and Glinski et al [7] was found to be dependent on defective function of T lymphocytes [8] . Furthermore, the reduction in E rosettes and decreased DNCB sensitization in psoriasis was related to the activity of the disease, but not to the extension of skin lesions [1, 7] . The supression of E rosette formation could be restored by in vitro short-term preincubation of psoriatic lymphocytes with Con A, and disappeared during remission of the disease [8] .
Finally, the sera of patients with psoriasis were found to contain a factor inhibiting normal T lymphocyte E rosette function, the concentration of which increased within 2 mo of recent relapse of skin lesions [8l
The percentage of E rosette forming cells were also studied in patients with psoriasis receiving PUVA therapy. Cormane et al [9, 10] have observed decrease in the number of rosetting lymphocytes in the patients and normal controls after 4 PUV A exposmes. The percentage of E rosettes returned to the starting range after 8 PUVA exposures, but was still significantly lower in psoriatics than in normals.
A marked reduction in E rosettes and normal number ofEAC rosettes in PUVA-treated patients were reported by Ortonne et al [11] . The initial percentage of E rosette forming cells in those patients was found to be normal. Unfortunately, there were no data concerning clinical state of patients with psoriasis, the number and frequency of PUV A exposures, and the time relation of the E rosette test to t he last PUV A irradiation.
The purpose of our paper was to determine a short-term effect of individual PUV A exposure as well as a long-term effect of PUV A therapy on peripheral blood lymphocytes forming E rosettes in patients with psoriasis with varying activity and extent of skin lesions.
MATERIALS AND METHODS

S election of Patients
58 patients with psoriasis vulgaris receiving PUV A photochemotherapy were studied. Control group consisted of 5 patients treated with PUV A for other purposes (2 urticaria pigmentosa, 2 vitiligo and 1 pre-mycosis fungoides), and 26 normal volunteers. Two clinical criteria were used for classification of patients with psoriasis: 1. activity of the disease, and 2. extent of skin lesions. The activity of cutaneous lesions was defined as: A2-pin-point lesions, small, papules spreading, positive Kobner phenomenon; Al-active spreading peripheraUy plaque lesions with only occasionally small papules; and AO-skin lesions stationary for a long period of time (more than 3 mol. The extent of skin changes was also graded in terms of surface occupied by psoriatic lesions: Blless than 10%, B2-10-40%, and B3-more than 40%.
Patients with psoriasis had never received PUV A photochemotherapy, and corticosteroids or immunosuppressive drugs systemically before they were included into the study. Prior to PUV A therapy the patients had been only treated externally with tars, corticosteroid oin tments, anthralin and salycilic acid.
To obtain comparable results individuals who were extremely sensitive to sunlight have not been included into our experiments.
P U V A Treatment
8-m eth oxy psoralen (8 MOP) (Methoxalen, Westwood Pharm. Inc. ) was administered ora lly in doses of 0.8-0.9 mg/ kg body weigh t 2 hI' be fo r e UV A irradiation.
U VA li gh t source was a 4-well stand -up cabinet containing 112 60 c m-long flu o rescent lamps in a horizontal plane. This source emits a con t inuous spec trum of irradiation between 320-400 nm wave length w it h peak emission at 365 nm. The energy delivered was on average 2.7-3 .5 mw/c m" at a distance of 10 em from th e flu oresce nt la mps.
The patients were irradiated in an alte rn ate day schedul e (excluding S und ay ) 3 t imes a wee k. The dose of UV A used fo r the first 3 P UV A exp osures varied from 2.4 to 2.7 J /cm", and starting from th e 4t h UV A irradi ation a dose was increased to 3.2-3.6 J / cm". Number of PU VA ex p osures necessar y for cl earing of psori atic lesions vari ed from 12 to 25 (ave rage 15.1) in this group of pa tients. T otal UV A dose received by indiv idua l patient was a bout 35-78 J /c m" (mea n 49 J / cm").
T iming of S ep arate Exp eriments
T hree different schedules of blood drawing fo r the determin ation of E r osette formin g cells were used: A. for eac h patient: l. before t he PUV A therapy; 2. after every 3 PUV A irradiations (once a week) on a d ay of in termission between 2 co nsecut ive PUV A exposures (3rd and 4th, 6th and 9th, 9th and lOt h, etc. ; and 3. 1 mo a fter complet io n of PUVA t herapy.
B . A t differen t tim es of P UVA treatmen t (P UVA expos ure [1-18]) twi ce da ily: just before oral administration of 8MO P and 2 hl' before UV A irradiation, and 1 hr after PUV A exposure.
C. Between two consecut ive PUVA exposures (N o. 3-4, 4-5, or 5-6): 2 h I' before PU V A exposure, 1 hr a fter P UV A irradiation, 24 hI' a fte r PUV A exposure, and 48 hr afte r P UV A exposure (just before administration of 8 MO P prior to th e next PUVA irradiation) .
E Rosette T est
Periph eral blood lymphocy tes were isolated on a Ficoll-Ronpaco n gradi ent of specific gravity 1.078 by a method desc ribed by Boy um [ 12 ] . S po nta neo us rosette forma t ion wi th sheep erythrocytes (SHBC) by lymphocytes was studied by a modification of th e method ofW ybra n et a l (13) .
B riefl y, S RBC were wash ed 3 times in H a nks' medium and cent rifu ged at 400 xg for 5 min . 0.2 ml of lymphocyte suspension (4 X 10'/ mI) was added to 0. 2 011 of 0.5% v/ v washed S RB C, a nd 0.2 ml heatin ac tiv ated S RB C-abso rbed fetal calf serum. Lymphocyte:el'ythrocyte ratio was 1:10. The mixture was incubated for 45 min at 37°C, centrifuge d at 200 xg fo r 5 min, and kept overnight at 4°C. Lymphocytes surrounded by 3 or more erythrocytes were consid ered as E rosettes. The percentage of lymphocytes forming E rosettes wi th SRB C was calculated for 400 consecut iv e lymphocytes.
T ests were done in duplicate for eac h patient and mean results acce pted if the perce ntage of E rosettes in both samples differed by not m o re t han 5%.
RESULTS
Once a W eek Determination of E R osette Formation During P UVA Treatment
A . in relation to activity of the disease. Prior to PUVA t r eatment the percentage of E rosette formin g cells was found to be decreased in 70% of patients with psoriasis (23 out of 33) c ompared to normal controls. Most of these cases were distributed into both groups of patients with active skin lesions (A2 a nd AI). The initia tion of PUVA thera py induced the subsequent reduction of starting value of E rosettes in 42 % of cases (14 out of 33). This was shown almost exclusively in patients with inactive skin lesions (AO) who were found to have normal initial distribution of E rosette forming cells (62.3 %) before o n set of PUV A thera py.
In active psoriasis (group Al and A2) the per centage of E rosette forming cells incr eased gr adually between every 3 PUV A i.rradiations reaching the normal value of rosetting cells after 9 or 12 PUVA exposures respectively ( Fig 1) . P atients w ith inactive psoriasis (group AO) showed a m arked r eduction in E rosettes after 3 PUVA exposures (47.7%), which persisted aft er 6 PUVA (51.6%), but returned to normal range after 9 PUVA expos ures (60 .1%).
In t h e majority of patients t he increase in th e percentage of E rosette forming cells was correlated wit h t he flattening and disappearing of psoriatic lesions.
There was no decrease of t h e percentage of E rosettes wi thin th e first 2 weeks of P U V A treatment in control gr oups consisted of 3 normals and t h e 5 patients receiving ph otoch emoth erapy for oth er purposes.
B . in relation to the exten sion of shin. lesion.s. Examination after every 3 P U V A exposures showed no significa nt difference in the percen tage of E rosette forming cells between groups of patients wi th varying extent of skin involvem en t (B I, B2, and B 3) ( Fig 2) . An init ial mean per centage of E rosettes prior to PU V A th erapy, a nd t hat after 3 PUV A as well as 6 PUV A exposures were markedly decreased . In all t hese clinical groups E rosette formation after 9, 12, a nd 15 PUV A irradiations was found to be normal. The reduction of initial percen tage of E rosettes after I week of P U V A th era py (3 P UV A exposures) was relatively gr eater in group Bl and B 3 th an in gr oup B2. However , most of patients wit h inactive psoriasis was distributed in to these 2 groups. 
E Rosette Formation 1 Month after Completion of PUVA Treatment
PUV A therapy was effective in all our patients, whose psoriatic lesions cleared within 4-8 weeks and did not relapse for more than 1 mo despite of discontinuation of the treatment. Irrespectively of initial activity and extent of psoriatic lesions prior to PUV A 85% of patients (28 out of 33) free of skin lesions reacquired normal E rosette formation up to 1 mo after termination of PUV A therapy in contrast to only 30% of cases showing normal number of E rosettes before PUV A treatment (Table I) . The remaining 5 patients were found to have only a slight decrease in E rosettes compared to normal controls, but the percentage ofrosetting cells in these cases was much greater than that before starting of PUVA therapy. There was no difference between the mean percentage of E rosette forming cells in patients with psoriasis symptom-free for 1 mo after PUV A treatment and healthy normals.
Suppression of E Rosette Formation with Single PUVA E xposure
In patients with inactive psoriasis a reduction of the percentage of E rosette forming cells (47.2%) appeared as early as 1 hr after termination of individual PUV A exposure as compared to 64.1 % of E rosettes before PUV A irradiation (Table Il) . The suppression of E rosette formation was still present after 24 hr (52.0%), whereas after 48 hr just before the subsequent PUV A exposure .patients reacquired normal E rosette function (66.8%). Only a slight decrease of percentage of E rosette forming cells from 67.8% before PUV A exposure to 61.2% 1 Ill" after PUV A exposure was found in healthy normals. The difference between these 2 mean numbers of E rosettes was not statistically significant.
The decrease in the percentage of E rosettes was found in patients with psoriasis receiving 8 MOP followed by irradiation with UVA light (46.4%), but not treated with 8 MOP alone (65.8 %) or UVA alone (61.5%) (Table III) 
Effect of Single PUVA Exposure on Psoriatic Lymphocytes at Different Times of Photochemotherapy
The comparison of E rosette test before and 1 hr after PUV A exposure revealed that the percentage of E rosette forming cells was significantly reduced, up to 32% of lymphocytes, in 20 out of 29 patients with psoriasis studied at different times of PUV A therapy (Table IV) . The marked decrease of about one third of lymphocytes forming E rosettes (45.7%) within initial phase of therapy (1) (2) (3) (4) (5) PUVA exposures) was found in all patients, who previously had the normal percentage of E rosette forming cells (67.1%). In patients with active psoriasis with reduced initial percentage of E rosette forming cells (42.0%) only about 15% of lymphocytes were inhibited in their E rosette function by single PUV A exposure (35.7%). This was demonstrated in 5 of 9 these patients 1 hr after PUV A exposure in the first 2 weeks of PUV A treatment.
After further irradiations (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) PUVA exposures) 5 of 10 cases who showed a marked decrease in E rosettes were found to have persistent elevated psoriatic lesions. No reduction in E rosettes was observed in those almost free of skin lesions.
DISCUSSION
The present data implies that at least 2 distinct phenomena involving T lymphocyte subpopulaticns compete with each other during PUV A treatment of psoriasis, immediate suppression of T cells after PUV A and a gradual improvement in the T cell function with therapy.
Individual PUVA exposure immediately induced the suppression of T lymphocyte E rosette formation in patients with psoriasis, but not in normal controls. This lasted for more than 24 hr after inadiation, whereas before subsequent PUVA exposme 48 hr later T lymphocytes reacquired theil' normal function. These fmdings are in agreement with communications of Cormane et al [9, 10] and Ortonne et al [11] who reported on ." significa ntly different from group 1 (t-test) ; " = p < 0.002, a nd " = p < 0.01. " M ore t han 5% of lymphocytes below a n initial percentage of E rosettes before PUV A irradiation. " Actual activity of skin lesions impossible to assess precisely with regard to clinical improvem ent-before t reatment mostly active lesions.
the depression in E rosette number in patients receiving PUVA therapy. The inhibitory effect of PUVA exposure on peripheral blood lymphocytes of psoriatic patients was du e to combined 8 MOP and UV A action. 8 MOP alone and UV A light alone had no influence on the relative number of rosetting cells.
Since immediate suppression of E rosette formation with PUV A exposure occurred usually in the initial phase of the treatm ent (within the first 2 weeks) 01' after further irradiations only in patients whose skin lesions were relatively resistant, it seem ed to be related to the presence of psoriatic lesions of both active and inactive type.
In active psoriasis in respect of diminished initial number of E rosettes an additional reduction of the percentage induced by PUV A was relatively small. In contrast, the immediate suppression was found to be responsible in patients with inactive psoriasis for extreme reduction of rosetting T cells within initial phase of PUV A therapy from norma! level prior to the treatment to the range comparable to that of patients with active l esions. The gradual improvement ofE rosette format ion with PUVA therapy was found in patients with both active and inactive psoriatic lesions in whom lymphocyte subpopulations were followed up once a week on a day after every 3 PUV A exposures. At this time the immediate suppression of T cells caused by preceding PUV A exposure, if present, should be still demonstrated because it lasts for more than 24 hI'. T lymphocyte rosetting function became normal in the third week of PUV A tratment which was correlated to flattening of skin lesions.
Further irradiations (12) (13) (14) (15) PUV A exposures) did not induce t he immediate suppression of E rosette formation in patients with clinical improvement or in those almost free of skin lesions. T lymphocyte quantitation in this phase of PUV A and 1 mo after completion of the treatment remained normal in almost all cases irrespectively of initial disease activity and extent of psoriatic lesions. This is in agreement with our previous data on t h e restoration of T cell function in the remission of psoriasis [7, 8) .
The mecha nism of reduction in the percentage of T lymphocytes forming E rosettes dUJ'ing PUVA treatment is not clear.
In vitro irradiation of peripheral blood lymphocytes with PUVA was found to inhibit lymphocyt e transformation to nonspecific rnitogens [14] , and spontaneous incorporation of tritiated thy-midin e [1 5]. However, it is not clear if this effect could be due to either inhibition of DNA synthesis by 8 MOP-DNA photoadduct formation, or incr eased cell death in the phototoxic reaction.
The immediate inhibitory effect of PUV A exposure on T cells could b e related to: 1. the irradiat ion of recirculating lymphocytes in cutaneous infiltrates and capillaries with a PUVA dose adequate to inhibit T lymphocyte function (direct mech anism), and/ or (2) the release of inhibiting factors (i.e., immune complexes) from s kin lesions into t he circulation (indirect mechanism).
Close relation of the PUV A-induced depression of E rosette formation t o th e presence of skin lesions m ay argue for both an indirect mechanism of T cell inhibition and direct suppression of the fun ction of recirculating lymphocytes. It is quite clear that indirect inhibition related to released factors should disappear with clearing of psoriatic lesions. Similarly, the absence of diJ'ect immediate suppression of T cells in intermediate phase of PUV A treatm ent might be explained by th e disappearance of lymphocyte inftitration [16) and r educed blood flow through skin capillaries in healing cutan eous lesions [1 7) as well as an adequate protection against PUVA by hyperpigmented skin.
It should be stressed that PUV A appeared to be unable to suppress E rosette formation of more than on e half of T lymphocytes in patients with psoriasis. This could be also explained by direct or indirect mechanism of PUV A action. N ot all lymphocytes recirculating through th e skin could receive UV A dose adequate to inhibit their rosetting function. However, in active psoriasis in contrast to inactive psoriasis th e number of T cells which are sensitive to PUV A il'l'adiation is relatively low d espite of similar distribution of s kin lesions. In active psoriasis T lymphocytes migh t be all'eady inhibited with underly ing unknown factors (perhaps previously described blocking factors in psoriatic sera [8) . The defect of E rosette form ation in these patients could be unblocked in vitro by preincubation of lymphocytes with Con A [8) .
PUV A exposure m ay provoke the release of inhibiting factors from skin lesions, which s ubsequently inhibit E rosette formation, but only of T cell subpopulation exhibiting affinity to those factors. In inactive psoriasis T lymphocytes sensitive to the action of blocking fa ctors migh t be previously unaffected, so the greater number of T cells than in active psoriasis could be suppressed after release of inhibiting factors stimulated by PUV A irradiation.
The alternative mechanism of PUV A-induced inhibition of T cell function remains to be elucidated.
